Syra Health Announces Closing of $2.1 Million Public Offering
Summary
The Series A warrants expire on the eighteen-month anniversary of the initial issuance date and the Series B warrants expire on the five-year anniversary of the initial issuance date.Rodman & Renshaw LLC acted as the exclusive placement agent for the offering.The aggregate gross proceeds to the Company from the offering were approximately $2.1 million before deducting the placement agents fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the Series Warrants, if fully exercised on a cash basis, will be approximately $4.1 million. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and the government. The forward-looking statements contained in this press release are based on managements current expectations and are subject to substantial risks, uncertainty, changes in circumstances and market and other conditions. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.For Investor or Media Inquiries:Syra HealthIR/PR and Marketing Director Christine Drury 317-385-9227